CPI‐203 improves the efficacy of anti‐PD‐1 therapy by inhibiting the induced PD‐L1 overexpression in liver cancer
Xiaoge Niu(Southern Medical University), Shuwen Liu(Zhengzhou University), Lin Li(Lanzhou Army General Hospital), Wei Wang(Capital Medical University), Chan Yang, Taizhen Liang(Southern Medical University), Xinfeng Xu(Southern Medical University), Shasha Li(Green Chemistry)
Cited by 9
Related Papers
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Underestimated health risks: polystyrene micro- and nanoplastics jointly induce intestinal barrier dysfunction by ROS-mediated epithelial cell apoptosis
|Particle and Fibre Toxicology|2021|487
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
|Drug Resistance Updates|2022|257